Chinatsu Nishioka, Yuki Tahata, Kazuki Maesaka, Machiko Kai, Kumiko Shirai, Kazuhiro Murai, Yuki Makino, Yoshinobu Saito, Yasutoshi Nozaki, Tasuku Nakabori, Hisashi Ishida, Takayuki Yakushijin, Sadaharu Iio, Nobuyuki Tatsumi, Kazuho Imanaka, Naruyasu Kakita, Ryotaro Sakamori, Atsushi Hosui, Masanori Miyazaki, Kengo Matsumoto, Masanori Nakahara, Yoshinori Doi, Mitsuru Sakakibara, Hayato Hikita, Takahiro Kodama, Tetsuo Takehara. "Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma." PLoS ONE (2026). https://doi.org/10.1371/journal.pone.0341395